Sep 26 |
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics
|
Sep 12 |
Viridian Therapeutics slides on pricing $225M securities offering
|
Sep 12 |
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
|
Sep 10 |
Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
|
Sep 10 |
Viridian Therapeutics announces proposed underwritten offering
|
Sep 10 |
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
|
Sep 10 |
Biggest stock movers today: ORCL, RBRK, VRDN, and more
|
Sep 10 |
Viridian posts initial late-stage trial data for lead asset
|
Sep 10 |
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
|
Sep 9 |
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
|